Cormorant Asset Management logo

Cormorant Asset Management

Pitchbook
Crunchbase

Deals on record

12

Common Fundraising Type

Series A

Numab Therapeutics is a biotech company that develops multi-specific antibody-based immunotherapies for inflammation and cancer.

Series C
$55M
01/10/2025
Article
Orbis Medicines logo
Orbis Medicines

Oral macrocycle drugs

Orbis Medicines develops oral macrocycle drugs as alternatives to biologic drugs using their nGen platform, which combines automated chemistry and machine learning.

Series A
$92.7M
01/06/2025
Article
nChroma Bio logo
nChroma Bio

Epigenetic editing

Wilson Sonsini Goodrich & Rosati logo
Wellington Management logo
T. Rowe Price logo
Sofinnova Partners logo
Sixth Street logo
Omega Funds logo
Mubadala Capital logo
Menlo Ventures logo

nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Equity
$75M
12/11/2024
Article
Axonis Therapeutics logo
Axonis Therapeutics

Biotechnology

venBio Partners logo
Sofinnova Investments logo
Solasta Ventures logo
SCI Ventures logo
Tachyon Ventures logo
Perceptive Advisors logo
MRL Ventures Fund logo
Lumira Ventures logo

Axonis Therapeutics is a biotechnology company developing novel neuromedicines targeting neurological disorders like epilepsy and pain.

Series A
$115M
10/30/2024
Article

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series B
$115M
10/02/2024
Article
GC Therapeutics logo
GC Therapeutics

Synthetic biology

GC Therapeutics (GCTx) develops off-the-shelf iPSC-based cell therapy products for gastrointestinal, neurological, and immunological diseases using their innovative TFome platform.

Series A
$65M
09/27/2024
Article
Supira Medical logo
Supira Medical

Medical Device Development

Supira Medical, Inc. is developing the Supira System, a percutaneous ventricular assist device (pVAD) designed to provide hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients.

Series D
$40M
11/21/2023
Article

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series A
$92M
10/26/2023
Article

Series B
$35M
10/03/2023
Article
Star Therapeutics logo
Star Therapeutics

Biotechnology

Sofinnova Investments logo
Westlake Village BioPartners logo
OrbiMed logo
Redmile Group logo
RA Capital Management logo
Qatar Investment Authority logo
New Leaf Venture Partners logo
NYBC Ventures logo

Star Therapeutics is a biotechnology company that develops first-in-class antibody therapies, primarily for hematology and immunology, and also generates additional biotech companies focused on discovering and advancing novel antibody therapies.

Series C
$90M
09/05/2023
Article
FORE Biotherapeutics logo
FORE Biotherapeutics

Precision Oncology

FORE Biotherapeutics is a precision oncology company that focuses on the clinical development of plixorafenib, a novel small-molecule inhibitor for treating BRAF-altered tumors.

Series D
$75M
08/23/2023
Article

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.

Series B
$150M
08/23/2023
Article